Jiangsu Tasly and Changchun Haiyue Win Bids for Tadalafil in China's Second Round of National Volume-Based Procurement

This morning, the second batch of national volume-based procurement officially kicked off, with corporate bidding results being released successively.

In this round of centralized procurement bidding, five companies submitted bids for tadalafil: Changchun HaiYue Pharmaceutical Limited By Share Ltd., Qilu Pharmaceutical (Hainan), Chia-Tai Tianqing (Nanjing), Eli Lilly, and Jiangsu Tasly Pharmaceutical. Based on the bid prices, Jiangsu Tasly Pharmaceutical and Changchun HaiYue Pharmaceutical won the bids with per-tablet arithmetic prices of 42.4 and 47.0304, respectively. Although Qilu Pharmaceutical’s bid ranked third, it was unsuccessful because its price exceeded 1.8 times that of Tasly’s and more than 50% of the maximum declared price limit. Nanjing Chia-Tai Tianqing and Eli Lilly were also eliminated.